![制造,步骤1 制造,步骤1](/sites/novartis_com/files/styles/crop_freeform/public/2021-10/manufacturing-step-1-image.png.webp?itok=CX9Vf6oc)
![制造,步骤2 制造,步骤2](/sites/novartis_com/files/styles/crop_freeform/public/2021-10/manufacturing-step-2-image.png.webp?itok=zTbu8bAD)
![制造,步骤3 制造,步骤3](/sites/novartis_com/files/styles/crop_freeform/public/2021-10/manufacturing-step-3-image.png.webp?itok=P5NULQqw)
![制造,步骤4 制造,步骤4](/sites/novartis_com/files/styles/crop_freeform/public/2021-10/manufacturing-step-4-image.png.webp?itok=PT5FEihW)
![制造,步骤5 制造,步骤5](/sites/novartis_com/files/styles/crop_freeform/public/2021-10/manufacturing-step-5-image.png.webp?itok=wlUFd_Q3)
空气质量差
Novartis Gene Therapies is committed to manufacturing excellence.Gene therapies can be reliably produced and delivered to patients with rare and chronic genetic disorders Many safeguards are in place to develop safe and high-quality gene therapies.The active lab facilities have ample storage,backup generators,and real-time alarm systems For every person involved in the process,there is a second,real-time verifier as well as aquality reviewer.There is also continuous monitoring of all operations and extensive testing throughout production Novartis Gene Therapies efficiently produces a supply of gene therapy.Redundant raw-material suppliers are used,and operations run24/7and365 days a year